Journals / Astım Allerji İmmünoloji / 2017 / Cilt: 15 - Sayı: 1

An Unusual Trigger for Cutaneous Mastocytosis: The Insulin Pump

Kutanöz Mastositozun Nadir Bir Tetikleyicisi: İnsülin Pompası

Pages
55–59
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Herein, we present for the first time, a patient with type 1 diabetes mellitus and cutaneous mastocytosis who developed exacerbation of lesions during insulin pump therapy

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Mastocytosis is a relatively infrequent disorder characterized by mast cell proliferation within primarily the skin, but also various organs such as the bone marrow, liver, spleen, lymph nodes and the gastrointestinal system.
📊
Key Findings & Data:A 13-year-old boy with cutaneous mastocytosis and type 1 diabetes mellitus developed multiple itchy papules 2 to 3 days after he started receiving insulin (lispro) pump therapy.
💡
Conclusion & Impact:Herein, we present for the first time, a patient with type 1 diabetes mellitus and cutaneous mastocytosis who developed exacerbation of lesions during insulin pump therapy
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Mastocytosis is a relatively infrequent disorder characterized by mast cell proliferation within primarily the skin, but also various organs such as the bone marrow, liver, spleen, lymph nodes and the gastrointestinal system. Several factors are known to induce symptoms in patients with mastocytosis. A 13-year-old boy with cutaneous mastocytosis and type 1 diabetes mellitus developed multiple itchy papules 2 to 3 days after he started receiving insulin (lispro) pump therapy. Punch biopsy revealed widespread mast cell infiltration on the papillary dermis. We hypothesized that the insulin pump catheter caused a physical stimulus due to local microtrauma and resulted in the formation of the lesions. We, therefore, discontinued insulin pump treatment and switched to SC insulin therapy. While previous lesions healed successfully, no new lesions occurred. To confirm our hypothesis, we repeated the procedure and observed the occurrence of similar lesions around the insulin pump catheter. Herein, we present for the first time, a patient with type 1 diabetes mellitus and cutaneous mastocytosis who developed exacerbation of lesions during insulin pump therapy

Özet

Mastositoz cilt başta olmak üzere kemik iliği, karaciğer, dalak, lenf nodları ve gastrointestinal sistemde mast hücrelerinin klonal artışı karakterize nadir görülen bir hastalıktır. Bazı faktörlerin mastositozlu hastaların semptomlarını tetiklediği bilinmektedir. Bu yazıda, Tip 1 diabetes mellitus (DM) olan hastada, insülin pompa tedavisine bağlı semptomları tetiklenen kutanöz mastositoz olgusu sunulmuştur. Kutanöz mastositoz ve Tip 1 DM tanısı konulan 13 yaşındaki erkek çocukta, insülin pompa ile verilen insülin lispro tedavisinden 2-3 gün sonra meydana gelen çok sayıda kaşıntılı papüler lezyonlar görüldü. Mastositoz olarak değerlendirilen lezyonlardan alınan punch biyopside papiller dermiste yaygın mast hücre infiltrasyonu görüldü. Mevcut bulgulardan yola çıkarak, insülin pompa kateterinin lokal mikro travma ile fiziksel uyaran oluşturduğu ve mastositoz lezyonlarının buna bağlı meydana geldiği düşünüldü. Pompa insülin tedavisi kesilip kateter uygulamasından vazgeçildi. İzleminde yeni lezyon çıkmadığı ve gluteal ve periumblikal bölgedeki lezyonların da hiperpigmentasyon ile düzeldiği görüldü. Doğrulama için yeniden insülin pompa kateteri takılan yerlerde 3 gün sonra aynı lezyonlar tekrarladı. Bu olgu nedeniyle, en az 48 saatlik süre boyunca cilt altında kalan kateterin, mastositozda lezyonları tetikleyebileceğini literatürde ilk defa ortaya koyduk

🔖

Cite This Article

AKELMA, Z., BULUŞ, A. D., KOÇAK, M., GÜNBEY, S., ANDIRAN, N., ŞİMŞEK, Z. G. (2017). An Unusual Trigger for Cutaneous Mastocytosis: The Insulin Pump. Astım Allerji İmmünoloji, Cilt: 15 - Sayı: 1, 55–59. https://ajindex.com/articles/145940

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Cohen SS, Skovbo S, Vestergaard H, Kristensen T, Moller M, Bindslev-Jensen C, et al. Epidemiology of systemic mastocytosis in Denmark. Br J Haematol 2014;166:521-8
  2. Theoharides TC, Valent P, Akin C. Mast Cells, Mastocytosis, and related disorders. N Engl J Med 2015;373:163-72
  3. Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, et al. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol 2016;137:35-45
  4. Lange M, Lugowska-Umer H, Niedoszytko M, Wasag B, Limon J, Zawrocki A, et al. Diagnosis of Mastocytosis in children and adults in daily clinical practice. Acta Derm Venereol 2016;96: 292-7
  5. Akin C. Mast cell activation disorders. J Allergy Clin Immunol Pract 2014;2:252-7
  6. Bonadonna P, Lombardo C, Zanotti R. Mastocytosis and allergic diseases. J Investig Allergol Clin Immunol 2014;24:288-97
  7. Brockow K. Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin North Am 2014;34:283-95
  8. Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: A study on history, clinical features and risk factors in 120 patients. Allergy 2008;63:226-32
  9. Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care 2003;26:1142-6
  10. Bruttomesso D, Pianta A, Crazzolara D, Scaldaferri E, Lora L, Guarneri G, et al. Continuous subcutaneous insulin infusion (CSII) in the Veneto region: Efficacy, acceptability and quality of life. Diabet Med 2002;19:628-34
  11. Cengiz E, Tamborlane WV, Martin-Fredericksen M, Dziura J, Weinzimer SA. Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: Results of glucose clamp studies in youth with type 1 diabetes. Diabetes Care 2010;33:1009-12
  12. Jeitler K, Horvath K, Berghold A, Gratzer TW, Neeser K, Pieber TR, Siebenhofer A. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 2008;51:941-51
  13. Misso ML, Egberts KJ, Page M, O’Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev 2010:CD00510